The glucagon-like peptide-1 mental-health story changed.
It did not disappear.
In 2026, FDA requested removal of suicidal behavior and ideation warnings from glucagon-like peptide-1 receptor agonist labels after finding no increased risk. [1]
That is important. Outdated warning language should not be repeated as if it is settled current labeling.
Glucagon-like peptide-1 medicines are still prescription care, and mental-health history still belongs in a clinician visit.
Evidence does not show a clear increased risk
A real-world cohort study compared semaglutide with non-glucagon-like peptide-1 anti-obesity or diabetes medicines. In patients with overweight or obesity, semaglutide was associated with lower risk of incident and recurrent suicidal ideation during six-month follow-up. The authors concluded the findings did not support higher risk. [2]
A 2025 systematic review and meta-analysis of randomized trials found suicide-related event incidence was very low: 0.047 per 100 person-years with glucagon-like peptide-1 medicines and 0.042 per 100 person-years with placebo. The rate ratio was 0.76, with a 95% confidence interval of 0.48 to 1.21. [3]
That is reassuring, but not the same as ignoring mental health.
Menopause can overlap with mood, sleep, and appetite
After menopause, a weight visit can involve sleep disruption, anxiety, depression history, antidepressants, alcohol use, appetite change, body-image distress, or past eating-disorder symptoms.
Those issues affect safety and adherence even when the glucagon-like peptide-1 label warning changes.
Red-flag triage still belongs in the visit
| Signal | Why it changes the plan |
|---|---|
| Current suicidal thoughts or self-harm urges | This needs urgent mental-health or emergency support, not routine medication messaging. |
| Severe mood change, agitation, psychosis, or inability to stay safe | These are safety red flags regardless of the medicine involved. |
| Active eating-disorder symptoms | Appetite-suppressing treatment can interact with restriction, bingeing, purging, or body-image distress. |
| Severe insomnia, alcohol escalation, or substance-use relapse | These can worsen mood stability and medication adherence. |
| Recent psychiatric medication changes | Side effects and symptom changes need context before blaming or clearing a glucagon-like peptide-1. |
In the United States, people with suicidal thoughts or immediate emotional crisis can call or text 988 for crisis support. [4] If someone is in immediate danger, emergency services are the safer path.
Decision checkpoint: what changes the plan
| Signal | Why it changes the plan | What to do next |
|---|---|---|
| Dose escalation is causing worsening nausea, constipation, reflux, or low intake | Titration is a safety and adherence decision, not just a calendar event. | Review dose timing, hydration, bowel plan, nutrition, and whether escalation should wait. |
| Severe abdominal pain, repeated vomiting, dehydration, or gallbladder-type pain | Labels treat pancreatitis, gallbladder disease, kidney injury from volume depletion, and severe gastrointestinal reactions as warning-level issues. | Ask for clinician instructions rather than self-adjusting or pushing through. |
| Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 | glucagon-like peptide-1 and dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 labels include boxed-warning and contraindication language for this history. | Do not treat eligibility as a weight-only decision. |
| Diabetes medicines, blood-pressure medicines, or procedure plans are involved | Appetite, glucose, fluid status, delayed gastric emptying, and anesthesia planning can interact. | Put the medication list, last dose date, symptoms, and procedure timing in one plan. |
| A compounded, research-use, or self-measured product is being considered | Product source and dose accuracy become part of the risk, not a minor logistics issue. | Anchor the discussion to approved labels and clinician monitoring. |
Evidence boundary
The point, for anyone weighing emotional changes on treatment, is not simply that glucagon-like peptide-1 medicines can work. The distinction that matters more for mood and mental-health monitoring is between trial efficacy and patient-specific fit. For the mental-health safety signal, the product labels themselves already set out contraindications, warnings, escalation, product-specific adverse reactions, pregnancy cautions, hypoglycemia risk with diabetes medicines, kidney-dehydration monitoring, gallbladder concerns, pancreatitis symptoms, and procedure disclosure. [5] [6]
The reason it matters after menopause, with emotional changes on treatment in view, is that weight loss can overlap with constipation, reflux, gallbladder history, kidney vulnerability during dehydration, muscle and bone preservation, sleep apnea, diabetes prevention, and medication changes. A page on mood and mental-health monitoring that ignores those tradeoffs may still rank for a query, but it does not help the reader make a safer decision.
The useful job of the evidence around the mental-health safety signal is to split three questions: whether the drug class fits, whether this specific product and dose path fit, and whether current symptoms mean the plan needs to slow down or change. For emotional changes on treatment, outcome trials and standards of care can strengthen the metabolic context, but they still do not remove label-based warnings or individualized screening. [6]
What this changes at the visit
When mood and mental-health monitoring is the reason for the visit, bring the exact product name, dose, last dose date, dose-escalation stage, bowel pattern, nausea or reflux severity, hydration status, protein intake, diabetes medicines, kidney history, gallbladder history, thyroid-cancer family history, surgery plans, and any compounded-product details. When the mental-health safety signal is the concern, a clinician does not need a flawless daily log. Around emotional changes on treatment, a clinician needs enough signal to judge whether this calls for routine monitoring, a slower titration, a medication switch, or a red-flag evaluation.
What to ask a clinician
Ask:
- Based on the current FDA update, what mental-health warning language applies to my specific medication?
- Should my depression, anxiety, insomnia, alcohol use, eating-disorder history, or psychiatric medicines change the plan?
- What mood or behavior changes should make me contact you before the next dose?
- If appetite suppression feels psychologically unsafe, should we slow escalation, pause, or use a different strategy?
- Who should I contact after hours if suicidal thoughts, self-harm urges, or severe mood symptoms appear?
The practical middle ground
The FDA update should lower unnecessary fear, but it should not remove screening. A careful intake can document baseline mood, sleep, alcohol use, eating patterns, current psychiatric medicines, and whether weight loss itself has been emotionally destabilizing in the past. Follow-up can then compare new symptoms with that baseline instead of guessing. That is better than either extreme: treating every mood symptom as a glucagon-like peptide-1 emergency, or treating the label update as permission to ignore mental health.
Evidence limits and who this fits
The evidence is limited when the FDA label update is used to erase individual mental-health screening. FDA's review did not find an increased class risk signal, but that does not mean depression, anxiety, eating-disorder history, insomnia, alcohol use, or suicidal thoughts can be ignored in one patient's weight-treatment plan. [1] [4]
This page fits women who need a current, non-alarmist glucagon-like peptide-1 mental-health screen. It is a poor fit for self-managing suicidal thoughts, self-harm urges, severe mood changes, mania symptoms, or psychologically unsafe appetite suppression without urgent support.
Bottom line
Use current FDA language. Do not overstate a suicidal-thought warning that FDA has asked to remove.
Also do not turn glucagon-like peptide-1 care into a mood-blind transaction. Ask about mood history, eating-disorder history, sleep, alcohol, current psychiatric medicines, and urgent safety symptoms. Suicidal thoughts or self-harm urges need immediate help, regardless of what caused them.
Related reading:
- glucagon-like peptide-1 Muscle Loss After Menopause.
- glucagon-like peptide-1 Side Effects After Menopause.
- glucagon-like peptide-1 Thyroid Warnings After Menopause.
References
[1] FDA. FDA requests removal of suicidal behavior and ideation warning from GLP-1 receptor agonist labels. https://www.fda.gov/drugs/drug-safety-communications/fda-requests-removal-suicidal-behavior-and-ideation-warning-glucagon-peptide-1-receptor-agonist-glp
[2] Wang W, Volkow ND, Berger NA, Davis PB, Kaelber DC, Xu R. Association of semaglutide with risk of suicidal ideation in a real-world cohort. Nat Med. 2024;30(1):168-176. doi:10.1038/s41591-023-02672-2 https://pubmed.ncbi.nlm.nih.gov/38182782/
[3] Ebrahimi P, Batlle JC, Ayati A, et al. Suicide and Self-Harm Events With GLP-1 Receptor Agonists in Adults With Diabetes or Obesity: A Systematic Review and Meta-Analysis. JAMA Psychiatry. 2025;82(9):888-895. doi:10.1001/jamapsychiatry.2025.0091 https://pubmed.ncbi.nlm.nih.gov/40105856/
[4] 988 Suicide & Crisis Lifeline. https://988lifeline.org/
[5] DailyMed. WEGOVY semaglutide injection and tablet prescribing information, revised June 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
[6] DailyMed. ZEPBOUND tirzepatide injection prescribing information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b